Non-Interventional, Retrospective, Multicenter Study on the Renal Safety of Liposomal Amphotericin B in Critically Ill Patients with Invasive Pulmonary Aspergillosis

Purpose

This study aims to determine the incidence of kidney injury associated with liposomal amphotericin B (L-AmB) treatment, based on RIFLE criteria, in patients admitted to the intensive care unit (ICU) with invasive pulmonary aspergillosis (IPA). Materials and Methods: A retrospective, multicenter observational study including patients treated with L-AmB for IPA while admitted to the ICU between 1 January 2015, and 31 December 2022.